Fibroblast Growth Factor 4 Gene Therapy for Chronic Ischemic Heart Disease

Navin K. Kapur, Jeffrey J. Rade

Research output: Contribution to journalReview articlepeer-review

Abstract

Therapeutic myocardial angiogenesis and arteriogenesis represent a novel treatment strategy for patients with angina refractory to traditional medical and surgical therapies. The fibroblast growth factors are a family of proteins that are known mediators of angio-/arteriogenesis. Based on promising preclinical animal data, a series of four randomized placebo-controlled clinical trials have been conducted to determine the safety and efficacy of local delivery of fibroblast growth factor 4 with the use of adenovirus-vector-mediated gene transfer to induce myocardial angio-/arteriogenesis in patients with stable angina. This review describes the scientific rationale underlying these clinical trials, provides an overview of their results, and discusses the implications for future studies.

Original languageEnglish (US)
Pages (from-to)133-141
Number of pages9
JournalTrends in Cardiovascular Medicine
Volume18
Issue number4
DOIs
StatePublished - May 2008

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Fibroblast Growth Factor 4 Gene Therapy for Chronic Ischemic Heart Disease'. Together they form a unique fingerprint.

Cite this